Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

This randomised, quadruple-blind, parallel-group proof-of-concept trial evaluates COMP360 psilocybin (25 mg vs 1 mg) administered with psychological support in adults meeting DSM-5 criteria for anorexia nervosa.

Primary purpose is treatment; outcomes include clinical-effectiveness measures and safety assessments. Sites include centres in the United States, Ireland and the United Kingdom.